Clinical AdvancementsThe initiation of a triplet combination study in frontline acute myeloid leukemia represents a significant advancement under the Cooperative Research and Development Agreement with the National Cancer Institute.
Financial StabilityThe company ended the quarter with approximately $65.34 million in cash, which management believes should fund operations for at least the next 12 months.
Pipeline DevelopmentActinium Pharmaceuticals is making progress in its Actimab-A programs for treating acute myeloid leukemia, with a pivotal P2/3 study expected to start and initial data from a triplet study due to report.